How to use progestin in hormone replacement therapy: An animal experiment

Chinese Medical Journal

Volumn 114, Issue 2, 2001, Pages 173-177

  Sun, Aijun ^a   Wang, Jiedong ^b   Zhu, Pengdi ^b  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b NATIONAL RESEARCH INSTITUTE FOR FAMILY PLANNING   (China)

Author keywords

Continuous; Cyclic; Hormone replacement therapy; Mitotic index; Proliferating cell nuclear antigen index; Rat

Indexed keywords

CYCLINE; ESTRADIOL VALERATE; GESTAGEN; MEDROXYPROGESTERONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; ESTROGEN THERAPY; FEMALE; IMMUNOHISTOCHEMISTRY; MENOPAUSE; MITOSIS INDEX; NONHUMAN; OVARIECTOMY; RAT; UTERUS;

ANIMALS; DRUG ADMINISTRATION SCHEDULE; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; IMMUNOHISTOCHEMISTRY; MEDROXYPROGESTERONE; MITOTIC INDEX; MODELS, ANIMAL; OVARIECTOMY; PROGESTINS; PROLIFERATING CELL NUCLEAR ANTIGEN; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; UTERUS;

EID: 0035089923     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. van Keep PA. The history and rationale of hormone replacement therapy. Maturitas 1990;12:163-170.
2. Gambrel RD. Prevention of endometrial cancer with progestogens. Maturitas 1986;8:159-168.
3. Violet LF, Weiss NS, Chu J, et al. Progestogen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991; 338:274-277.
4. Samsioe GN, Mattsson LA. Regimens for today and the future. In: Rogerio AL, ed. Treatment of the postmenopausal woman. New York: Raven Press; 1994:373-383.
5. Wronski TJ, Yen CF. The ovariectomized rat as an animal model for postmenopausal bone loss. Cell Mater 1991;(Suppl):69-74.
6. Hall PA, Levison DA, Woods AI, et al. Proliferating cell nuclear antigen (PCNA) immunolocalize action in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasm. J Pathol 1990;162:285-294.
7. Sun AJ, Zhu PD, Lin SQ, et al. Study of the proliferation and inhibition under estrogen and progestogen in rat endometrium using Mitotic index and PCNA index. J Reprod Med 1997;6:32.
8. Christiansen MS, Hagen C. Dose-response evaluation of cyclic estrogen/gestagen in postmenopausal women: placebo controlled trial of its gynecologic and metabolic actions. Am J Obstet Gynecol 1982;144:873.
9. Leather AT, Studd JW. Can the withdrawal bleed following oestrogen replacement therapy be avoided? Br J Obstet Gynaecol 1990:97:1071-1074.
10. Sun AJ, Zhu PD, Lin SQ, et al. Study of the proliferation and inhibition under estrogen and progestogen in rat endometrium using Mitotic index and PCNA index. J Reprod Med 1997;6:32-34.
11. Sun AI, Zhu PD, Lin SQ, et al. Changes of Mitotic index and PCNA index in rat endometrium during the normal estrous cycle. J Reprod Med 1999;9:142-145.
12. Staland B. Continuous treatment with a combination of estrogen and gestagen - a way of avoiding endometrial stimulation. Acta Obstet Gynecol Scand 1985;130(Suppl):29-35.
13. Sporrong T, Hellgren M, Samsioe G, et al. Comparison of four continuously administered progestogen plus oestradiol combinations for climacteric complaints. Br J Obstet Gynaecol 1988;95:1042-1048.
14. Beresford AA, Weiss NS, Voigt LF, et al. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestogen therapy in postmenopausal women. Lancet 1997;349: 458.